Maryvonne Hourmant

Title: Maryvonne Hourmant: Innovator in Transplant Medicine

Introduction

Maryvonne Hourmant is a notable inventor based in Nantes, France. She has made significant contributions to the field of transplant medicine, particularly through her innovative research and patenting efforts. Her work focuses on improving the survival rates of organ transplants, which is a critical area in medical science.

Latest Patents

Maryvonne Hourmant holds a patent for a method aimed at increasing mean survival times of transplants using LFA-1-specific antibodies. This patent describes a process where the mean survival times of functional solid organ transplants in patients can be enhanced by administering an initial dose of a therapeutically effective amount of a monoclonal antibody directed against the human LFA-1 molecule within two hours after grafting. Following this, daily doses are administered over a period of approximately nine days. This innovative approach has the potential to significantly improve transplant outcomes.

Career Highlights

Throughout her career, Maryvonne Hourmant has been associated with Imtix-Sangstat, a company that focuses on developing therapies for transplant patients. Her work has been instrumental in advancing the understanding and treatment of transplant rejection, making her a key figure in this specialized field.

Collaborations

Maryvonne has collaborated with notable colleagues such as Gilles Alberici and Pierre Caudrelier. These partnerships have contributed to her research and the successful development of her patented methods.

Conclusion

Maryvonne Hourmant's contributions to transplant medicine through her innovative patent demonstrate her commitment to improving patient outcomes. Her work continues to influence the field and offers hope for better transplant survival rates in the future.